Healthcare provider profile · identity verified

Eric Moyer, MD

Family Practice · CLEVELAND, OH · NPI 1447479399

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	380	138
Amlodipine Besylate	Amlodipine Besylate	301	100
Rosuvastatin Calcium	Rosuvastatin Calcium	246	84
Losartan Potassium	Losartan Potassium	232	76
Lisinopril	Lisinopril	214	71
Metoprolol Succinate	Metoprolol Succinate	122	41
Metformin Hcl Er	Metformin Hcl	115	46
Gabapentin	Gabapentin	114	30
Hydrochlorothiazide	Hydrochlorothiazide	103	37
Levothyroxine Sodium	Levothyroxine Sodium	91	37
Omeprazole	Omeprazole	79	23
Tamsulosin Hcl	Tamsulosin Hcl	79	32
Eliquis	Apixaban	74	14
Pantoprazole Sodium	Pantoprazole Sodium	72	26
Metformin Hcl	Metformin Hcl	65	20
Simvastatin	Simvastatin	56	17
Finasteride	Finasteride	55	20
Alprazolam	Alprazolam	51	15
Potassium Chloride	Potassium Chloride	47	13
Jardiance	Empagliflozin	45	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	12
Alendronate Sodium	Alendronate Sodium	41	13
Fluticasone Propionate	Fluticasone Propionate	41	28
Escitalopram Oxalate	Escitalopram Oxalate	37	suppressed
Carvedilol	Carvedilol	34	15
Allopurinol	Allopurinol	33	15
Sertraline Hcl	Sertraline Hcl	33	18
Trazodone Hcl	Trazodone Hcl	33	14
Lorazepam	Lorazepam	32	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	30	18
Bupropion Xl	Bupropion Hcl	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	14
Mounjaro	Tirzepatide	28	suppressed
Spironolactone	Spironolactone	28	12
Furosemide	Furosemide	27	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	suppressed
Famotidine	Famotidine	25	12
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Atenolol	Atenolol	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Ozempic	Semaglutide	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Meloxicam	Meloxicam	19	11
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Prednisone	Prednisone	19	17
Tramadol Hcl	Tramadol Hcl	19	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Ramipril	Ramipril	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Minocycline Hcl	Minocycline Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Methylprednisolone	Methylprednisolone	11	11
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Topiramate	Topiramate	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error